Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oligo-fucoidan is a low-molecular-weight form of fucoidan, a complex sulfated polysaccharide primarily extracted from brown seaweed such as *Sargassum hemiphyllum*. Unlike high-molecular-weight fucoidan, the oligo form is characterized by enhanced bioavailability and solubility, making it more suitable for therapeutic applications. It exerts multi-targeted anti-tumor effects by inhibiting angiogenesis through the downregulation of vascular endothelial growth factor (VEGF), suppressing tumor cell migration and invasion via the HGF/c-Met pathway, and modulating the transforming growth factor beta (TGF-beta) signaling cascade. Additionally, oligo-fucoidan has been shown to enhance immune surveillance by activating natural killer (NK) cells and promoting a Th1-polarized immune response. It is primarily investigated as an adjuvant therapy in advanced hepatocellular carcinoma (HCC) and other solid tumors to improve clinical outcomes and reduce treatment-related toxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oligo-fucoidan.